NEW YORK, December 14, 2016 /PRNewswire/ --
Four Medical Appliances and Equipment equities have been selected for evaluation by Stock-Callers.com this morning, and they are Globus Medical Inc. (NYSE: GMED), ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Accuray Inc. (NASDAQ: ARAY), and ABIOMED Inc. (NASDAQ: ABMD). These stocks belong to the Healthcare sector which continued to rise for a third session in a row on Tuesday, December 13th, 2016. As per a report on the NASDAQ, the NYSE Health Care Index rose nearly 0.7%, while shares of health care companies in the S&P 500 climbed 0.9% as a group. Download the free research reports on these stocks today:
Audubon, Pennsylvania headquartered Globus Medical Inc.'s shares declined 0.66%, closing Tuesday's trading session at $24.09. The stock recorded a trading volume of 1.39 million shares, which was above its three months average volume of 1.09 million shares. Shares of the Company have advanced 12.31% in the last month and 8.51% over the previous three months. The stock is trading 7.97% above its 50-day moving average and 2.73% above its 200-day moving average. Additionally, shares of Globus Medical, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, have a Relative Strength Index (RSI) of 69.78.
On November 30th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock. See our free and comprehensive research report on GMED at:
On Tuesday, shares in Pleasanton, California headquartered ZELTIQ Aesthetics Inc. recorded a trading volume of 491,500 shares. The stock dropped 0.70%, ending the day at $43.75. The Company's shares have advanced 11.01% in the last month, 11.07% in the previous three months, and 53.35% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.76% and 32.78%, respectively. Furthermore, shares of ZELTIQ Aesthetics, which engages in developing and commercializing non-invasive products for the selective reduction of fat, have an RSI of 57.64.
On November 9th, 2016, Zeltic announced that total revenue for Q3 2016 was $95.2 million, consisting of $42.7 million of system revenue and $52.5 million of consumable revenue. This compared to total revenue of $61.2 million, consisting of $29.3 million of system revenue and $31.9 million of consumable revenue, for Q3 2015. The company's net income for Q3 2016 was $5.2 million, or $0.12 per diluted share, compared to net income of $2.1 million, or $0.05 per diluted share, for Q3 2015.
On December 7th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock, issuing a target price of $51 per share. ZLTQ free research report PDF is just a click away at:
Sunnyvale, California headquartered Accuray Inc.'s stock finished the day 0.96% lower at $5.15 with a total trading volume of 294,693 shares. The Company's shares are trading below their 50-day moving average by 2.67%. Shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have an RSI of 49.15.
On December 8th, 2016, Accuray announced that leading hospitals in Europe and the US are now treating patients with the new Radixact™ Treatment Delivery System, fully integrated with the new Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. The first patient treatment in the world was administered at the University Hospital Brussels in Belgium and in the US at Froedtert and the Medical College of Wisconsin Froedtert Hospital in Milwaukee, Wisconsin, part of the Froedtert & MCW Cancer Network. Sign up for your complimentary report on ARAY at:
Shares in Danvers, Massachusetts headquartered ABIOMED Inc. ended yesterday's session 0.34% lower at $118.66. The stock recorded a trading volume of 385,445 shares. The Company's shares have advanced 7.86% in the last one month, 0.12% over the previous three months, and 31.44% since the start of this year. The stock is trading 2.22% and 9.00% above its 50-day and 200-day moving averages, respectively. Moreover, shares of ABIOMED, which engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart, have an RSI of 57.46.
On December 7th, 2016, Abiomed announced that it has expanded its US FDA pre-market approval for Impella heart pump use in high-risk percutaneous coronary interventions to include the Impella CP® heart pump.
On December 7th, 2016, research firm Guggenheim initiated a 'Buy' rating on the Company's stock. Register for free on Stock-Callers.com and download the latest research report on ABMD at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA